Biotechnology

Keros Therapeutics

Oppenheimer Analyst Maintains Buy Rating on Keros Therapeutics

H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics

Keros Therapeutics released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 14.26 M (forecast USD 4.222 M), actual EPS USD -0.18 (forecast USD -1.02)

Keros Therapeutics released FY2025 9 Months Earnings on November 5 (EST), actual revenue USD 243.68 M, actual EPS USD 2.68

Keros Therapeutics Launches Stock Repurchase Program

Keros Therapeutics released FY2025 Semi-Annual earnings on August 6 (EST), actual revenue USD 229.41 M, actual EPS USD 2.86

Keros Therapeutics released FY2025 Q2 earnings on August 6 (EST), actual revenue USD 18.17 M (forecast USD 4.213 M), actual EPS USD -0.7599 (forecast USD -1.119)

Keros Therapeutics Launches Phase 3 Clinical Trial for elritercept

Keros Therapeutics Announces TROPOS Study Results and Company Changes

Keros Therapeutics Announces TROPOS Trial Results and Corporate Restructuring Plan

Keros Therapeutics Announces TROPOS Results and Undertakes Corporate Restructuring

Keros Therapeutics Reveals TROPOS Study Results and Company Restructuring

Keros Therapeutics Announces TROPOS Study Results and Organizational Changes

FactSet Surveyed Analysts Give Keros Therapeutics an Overweight Rating

B of A Securities Downgrades Keros Therapeutics to Neutral

Keros Therapeutics Annual Shareholders' Meeting Rejects Capital Allocation Proposals

Company Completes Strategic Alternatives Review and Updates Progress on KER-065 Development

Keros Therapeutics CEO Attends Goldman Sachs Healthcare Conference

Keros Therapeutics Announces TROPOS Results and Restructuring

D. E. Shaw & Co. Inc. Significantly Reduces Holdings in Keros Therapeutics

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Irobot

Toro

Springview

Dreamland

Praxis Precision Medicines

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap